|
Anacor Pharmaceuticals |
|
|
|
|
AstraZeneca |
|
|
|
|
Boston University |
|
|
|
|
CDC TBTC |
|
|
|
|
EDCTP |
|
|
|
|
German Center for Infection Research (DZIF) |
|
|
|
|
GlaxoSmithKline |
|
|
|
|
Global Alliance for TB Drug Development |
|
|
|
|
Hans-Knöll Institute, Jena |
|
|
|
|
iM4TB - Innovative Medicines for Tuberculosis |
|
|
|
|
Institute of Materia Medica |
|
|
|
|
IUATLD, Inc. |
|
|
|
|
Janssen Research & Development, LLC |
|
|
|
|
Lilly TB Drug Discovery Initiative |
|
|
|
|
Médecins Sans Frontières France |
|
|
|
|
Medecins Sans Frontieres, The Netherlands |
|
|
|
|
Michigan State University |
|
|
|
|
Microbiotix, Inc. |
|
|
|
|
Nearmedic Plus LLC |
|
|
|
|
NIAID, NIH, DHHS |
|
|
|
|
Novartis |
|
|
|
|
Otsuka Pharmaceutical Development & Commercialization, Inc. |
|
|
|
|
PanACEA |
|
|
|
|
Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund |
|
|
|
|
Qurient Co., Ltd |
|
|
|
|
Sanofi |
|
|
|
|
Sequella, Inc |
|
|
|
|
Spero Therapeutics, LLC |
|
|
|
|
SPRINT TB (National University of Singapore) |
|
|
|
|
St. George's Hospital University of London |
|
|
|
|
The Aurum Institute NPC |
|
|
|
|
University of Auckland |
|
|
|
|
University of Illinois at Chicago |
|
|
|
|
University of Munich |
|
|
|
|
USAID |
|
|
|
|
Weill Medical College of Cornell University |
|
|
|
